Corcept Therapeutics Inc (NASDAQ: CORT)

$50.75 ▼ -0.45 (-0.88%)

As of May 12, 2026 12:09 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001088856

Market Cap 4.84 Bn

P/E 49.05

P/S 6.36

Div. Yield 0.00

ROIC (Qtr) -0.05

Revenue Growth (1y) (Qtr) 4.89

Add ratio to table...

About

Corcept Therapeutics Inc is a commercial stage company focused on the discovery and development of medications that modulate the effects of the hormone cortisol to treat severe endocrinologic oncologic metabolic and neurologic disorders. The firm’s lead product Korlym is approved for the treatment of hypercortisolism also known as Cushing’s syndrome in the United States. In addition Corcept is advancing a pipeline of selective cortisol modulators such as relacorilant nenocorilant miricorilant and dazucorilant for indications including solid...

Corcept Therapeutics Inc is a commercial stage company focused on the discovery and development of medications that modulate the effects of the hormone cortisol to treat severe endocrinologic oncologic metabolic and neurologic disorders. The firm’s lead product Korlym is approved for the treatment of hypercortisolism also known as Cushing’s syndrome in the United States. In addition Corcept is advancing a pipeline of selective cortisol modulators such as relacorilant nenocorilant miricorilant and dazucorilant for indications including solid tumors metabolic associated steatohepatitis amyotrophic lateral sclerosis and other serious conditions.

Corcept generates revenue primarily from the sale of Korlym and its authorized generic version in the United States. The company promotes its products through a dedicated sales force that calls on physicians who treat patients with hypercortisolism. Revenue is also supported by patient assistance programs that help individuals afford therapy and by distribution arrangements with specialty pharmacy providers. All product sales are denominated in US dollars and reflect demand from healthcare providers prescribing the approved indications.

Corcept occupies a niche position within the pharmaceutical industry as a developer of cortisol modulating therapies. Its main competitors in the hypercortisolism market include Recordati’s Signifor Xeris’s Recorlev and Isturisa as well as generic versions of Korlym offered by Teva. The company’s competitive advantage stems from its portfolio of selective cortisol modulators that bind the glucocorticoid receptor without affecting the progesterone receptor thereby avoiding side effects such as endometrial thickening and vaginal bleeding. Additionally Corcept benefits from orphan drug designations for several of its pipeline assets which provide tax credits reduced fees and periods of market exclusivity upon approval.

Corcept serves physicians who treat patients with hypercortisolism solid tumors metabolic liver disease and amyotrophic lateral sclerosis. The company’s customers include endocrinologists oncologists gastroenterologists neurologists and other specialists who prescribe its approved and investigational products. Patients receiving therapy for these conditions represent the ultimate end users of Corcept’s medications.

Investment thesis

Bull case

Corcept’s recent guidance upgrade to $800 million through $850 million for the full year signals that market expectations have not yet fully absorbed the growing demand for its flagship product Korlym and the early pipeline momentum. The quarter’s 42.5 percent rise in tablet shipments and the continued record in the authorized generic segment demonstrate that the underlying sales engine is already operating at a scale that will support the revised revenue target. Management’s confidence is further bolstered by a strategic expansion of the specialty pharmacy network, with two additional partners slated to begin operations in early 2026, thereby eliminating the capacity bottleneck that constrained the previous vendor. Together, these factors indicate a strong upward trajectory that the current share price has not yet priced in.
The company’s robust sales force, now numbering 150 clinical specialists from an initial 60, has enabled deep penetration of the endocrinology market and accelerated prescriber engagement. A dedicated team focused on physician education is already translating emerging data from the CATALYST and MOMENTUM studies into increased awareness of hypercortisolism prevalence, creating a pipeline of new patients who may qualify for relacorilant once it receives approval. By positioning the company as the primary provider of cortisol modulation, Corcept is effectively creating a brand that can be leveraged across all therapeutic areas in its pipeline. This brand equity translates into a competitive moat that is difficult for other companies to replicate quickly.
The recent ROSELLA study results represent a breakthrough in the ovarian cancer space, with a 35 percent reduction in risk of death when relacorilant is added to nab‑paclitaxel. The trial’s 16.0 month median overall survival compared to 11.9 months for chemotherapy alone establishes the combination as a potential new standard of care in a field that has long struggled to achieve meaningful survival gains. Because relacorilant has oral administration and a well‑tolerated safety profile, the drug could be adopted rapidly by oncologists who currently rely on more toxic intravenous regimens. This therapeutic advantage is likely to translate into a significant share of the $20,000 to $30,000 annual treatment market in the United States alone.
The company’s orphan drug designation in the United States and Europe for both hypercortisolism and ovarian cancer provides an additional regulatory advantage that protects the product from generic competition for a minimum of 10 years. This exclusivity period ensures a period of monopoly pricing that can generate high gross margins, offsetting the incremental costs of commercialization. Furthermore, the authorization of a generic version at a 30 percent discount to the brand price suggests that Corcept is actively managing price sensitivity without sacrificing margin sustainability, a strategy that has already proven successful with Korlym.
Corcept’s strategic litigation against Teva over the Korlym generic is still in the appellate phase, and the court’s decision could potentially reinforce the company’s patent protection until 2037. If the appeal is successful, the company would effectively lock out generic competitors for nearly a decade, preserving the high net margin profile that has been the hallmark of the drug’s commercial performance. Even in the unlikely event that the appeal is denied, the current authorized generic volume is still around 75 percent of total sales, indicating that a transition to a lower priced product is already underway and will likely continue to drive incremental cash flow without significant margin erosion.

Corcept’s recent guidance upgrade to $800 million through $850 million for the full year signals that market expectations have not yet fully absorbed the growing demand for its flagship product Korlym and the early pipeline momentum. The quarter’s 42.5 percent rise in tablet shipments and the continued record in the authorized generic segment demonstrate that the underlying sales engine is already operating at a scale that will support the revised revenue target. Management’s confidence is further bolstered by a strategic expansion of the specialty pharmacy network, with two additional partners slated to begin operations in early 2026, thereby eliminating the capacity bottleneck that constrained the previous vendor. Together, these factors indicate a strong upward trajectory that the current share price has not yet priced in.
The company’s robust sales force, now numbering 150 clinical specialists from an initial 60, has enabled deep penetration of the endocrinology market and accelerated prescriber engagement. A dedicated team focused on physician education is already translating emerging data from the CATALYST and MOMENTUM studies into increased awareness of hypercortisolism prevalence, creating a pipeline of new patients who may qualify for relacorilant once it receives approval. By positioning the company as the primary provider of cortisol modulation, Corcept is effectively creating a brand that can be leveraged across all therapeutic areas in its pipeline. This brand equity translates into a competitive moat that is difficult for other companies to replicate quickly.
The recent ROSELLA study results represent a breakthrough in the ovarian cancer space, with a 35 percent reduction in risk of death when relacorilant is added to nab‑paclitaxel. The trial’s 16.0 month median overall survival compared to 11.9 months for chemotherapy alone establishes the combination as a potential new standard of care in a field that has long struggled to achieve meaningful survival gains. Because relacorilant has oral administration and a well‑tolerated safety profile, the drug could be adopted rapidly by oncologists who currently rely on more toxic intravenous regimens. This therapeutic advantage is likely to translate into a significant share of the $20,000 to $30,000 annual treatment market in the United States alone.
The company’s orphan drug designation in the United States and Europe for both hypercortisolism and ovarian cancer provides an additional regulatory advantage that protects the product from generic competition for a minimum of 10 years. This exclusivity period ensures a period of monopoly pricing that can generate high gross margins, offsetting the incremental costs of commercialization. Furthermore, the authorization of a generic version at a 30 percent discount to the brand price suggests that Corcept is actively managing price sensitivity without sacrificing margin sustainability, a strategy that has already proven successful with Korlym.
Corcept’s strategic litigation against Teva over the Korlym generic is still in the appellate phase, and the court’s decision could potentially reinforce the company’s patent protection until 2037. If the appeal is successful, the company would effectively lock out generic competitors for nearly a decade, preserving the high net margin profile that has been the hallmark of the drug’s commercial performance. Even in the unlikely event that the appeal is denied, the current authorized generic volume is still around 75 percent of total sales, indicating that a transition to a lower priced product is already underway and will likely continue to drive incremental cash flow without significant margin erosion.

Bear case

The FDA’s complete response letter for relacorilant in hypercortisolism indicates that the drug failed to meet the primary efficacy endpoint and raises serious liver safety concerns, with four patients experiencing probable drug‑induced liver injury. This regulatory setback suggests that the company will need to conduct additional trials to satisfy the agency, potentially delaying or preventing market entry for the drug’s flagship indication. The uncertainty around relacorilant’s approval timeline directly undermines the company’s projected $3 to $5 billion annual revenue from hypercortisolism over the next five years, casting doubt on the realism of those estimates.
Investor litigation alleging that the company misrepresented its regulatory interactions and the commercial potential of relacorilant signals a potential reputational crisis that could erode stakeholder confidence. The investigation by prominent law firms highlights the possibility of additional regulatory scrutiny and the risk of material adverse impact on the company’s valuation. A sustained loss of trust among investors could lead to higher cost of capital and restrict future financing options.
The increasing presence of generic competitors for Korlym, particularly with the authorized generic now accounting for 75 percent of total volume, threatens to erode the company’s gross margin. Management’s statement that margins will remain stable may be overly optimistic given the lower price point of the generic and the potential for further discounting as competition intensifies. Over time, margin compression could become a significant drag on profitability, especially if the company must lower prices to retain market share.
Corcept’s reliance on a single specialty pharmacy partner for the initial relacorilant launch introduces a bottleneck risk that could delay patient access and harm early adoption momentum. While the company plans to add additional pharmacies, the timeline for onboarding and scaling may not align with the FDA’s December 30 PDUFA deadline, potentially resulting in a lag between approval and widespread distribution. A delayed rollout would reduce the initial revenue window that is critical for recouping development costs.
The company’s pipeline concentration on glucocorticoid receptor antagonists, while innovative, creates a narrow therapeutic focus that could become a single point of failure if clinical outcomes fail to replicate in multiple indications. The high probability of attrition in early and late‑stage trials, combined with limited diversification outside this class, magnifies the risk that a failure in any key product could jeopardize the entire pipeline. This concentrated risk profile is a red flag for investors seeking more balanced portfolios.

The FDA’s complete response letter for relacorilant in hypercortisolism indicates that the drug failed to meet the primary efficacy endpoint and raises serious liver safety concerns, with four patients experiencing probable drug‑induced liver injury. This regulatory setback suggests that the company will need to conduct additional trials to satisfy the agency, potentially delaying or preventing market entry for the drug’s flagship indication. The uncertainty around relacorilant’s approval timeline directly undermines the company’s projected $3 to $5 billion annual revenue from hypercortisolism over the next five years, casting doubt on the realism of those estimates.
Investor litigation alleging that the company misrepresented its regulatory interactions and the commercial potential of relacorilant signals a potential reputational crisis that could erode stakeholder confidence. The investigation by prominent law firms highlights the possibility of additional regulatory scrutiny and the risk of material adverse impact on the company’s valuation. A sustained loss of trust among investors could lead to higher cost of capital and restrict future financing options.
The increasing presence of generic competitors for Korlym, particularly with the authorized generic now accounting for 75 percent of total volume, threatens to erode the company’s gross margin. Management’s statement that margins will remain stable may be overly optimistic given the lower price point of the generic and the potential for further discounting as competition intensifies. Over time, margin compression could become a significant drag on profitability, especially if the company must lower prices to retain market share.
Corcept’s reliance on a single specialty pharmacy partner for the initial relacorilant launch introduces a bottleneck risk that could delay patient access and harm early adoption momentum. While the company plans to add additional pharmacies, the timeline for onboarding and scaling may not align with the FDA’s December 30 PDUFA deadline, potentially resulting in a lag between approval and widespread distribution. A delayed rollout would reduce the initial revenue window that is critical for recouping development costs.
The company’s pipeline concentration on glucocorticoid receptor antagonists, while innovative, creates a narrow therapeutic focus that could become a single point of failure if clinical outcomes fail to replicate in multiple indications. The high probability of attrition in early and late‑stage trials, combined with limited diversification outside this class, magnifies the risk that a failure in any key product could jeopardize the entire pipeline. This concentrated risk profile is a red flag for investors seeking more balanced portfolios.

Class of Stock Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools